Premium
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III / IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
Author(s) -
Yokota Kenji,
Uchi Hiroshi,
Uhara Hisashi,
Yoshikawa Shusuke,
Takenouchi Tatsuya,
Inozume Takashi,
Ozawa Kentaro,
Ihn Hironobu,
Fujisawa Yasuhiro,
Qureshi Anila,
Pril Veerle,
Otsuka Yasushi,
Weber Jeffrey,
Yamazaki Naoya
Publication year - 2019
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.15103
Subject(s) - nivolumab , ipilimumab , medicine , adjuvant , hazard ratio , oncology , adjuvant therapy , subgroup analysis , melanoma , stage (stratigraphy) , gastroenterology , confidence interval , cancer , immunotherapy , cancer research , paleontology , biology
The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma ( N = 906). In this Japanese subgroup analysis of CheckMate 238 ( n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12‐ and 18‐month recurrence‐free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19–2.24; P = 0.4390). No new safety signals were reported for Japanese patients. Results were consistent with those from the CheckMate 238 global population, indicating that nivolumab has the potential to be a treatment option for Japanese patients with resected melanoma who are at high risk of recurrence.